|
1
|
Rathmann W and Giani G: Global prevalence
of diabetes: Estimates for the year 2000 and projections for 2030.
Diabetes Care. 27:2568–2569. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kopelman PG: Obesity as a medical problem.
Nature. 404:635–643. 2000.PubMed/NCBI
|
|
3
|
Saltiel AR: New perspectives into the
molecular pathogenesis and treatment of type 2 diabetes. Cell.
104:517–529. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bajaj M and Defronzo RA: Metabolic and
molecular basis of insulin resistance. J Nucl Cardiol. 10:311–323.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pendergrass M, Bertoldo A, Bonadonna R,
Nucci G, Mandarino L, Cobelli C and Defronzo RA: Muscle glucose
transport and phosphorylation in type 2 diabetic, obese
nondiabetic, and genetically predisposed individuals. Am J Physiol
Endocrinol Metab. 292:E92–E100. 2007. View Article : Google Scholar
|
|
6
|
Cusi K, Maezono K, Osman A, Pendergrass M,
Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR and Mandarino LJ:
Insulin resistance differentially affects the PI3-kinase- and MAP
kinase-mediated signaling in human muscle. J Clin Invest.
105:311–320. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Groop LC, Bonadonna RC, DelPrato S,
Ratheiser K, Zyck K, Ferrannini E and DeFronzo RA: Glucose and free
fatty acid metabolism in non-insulin-dependent diabetes mellitus.
Evidence for multiple sites of insulin resistance. J Clin Invest.
84:205–213. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bays H, Mandarino L and DeFronzo RA: Role
of the adipocyte, free fatty acids, and ectopic fat in pathogenesis
of type 2 diabetes mellitus: Peroxisomal proliferator-activated
receptor agonists provide a rational therapeutic approach. J Clin
Endocrinol Metab. 89:463–478. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee CH, Olson P and Evans RM: Minireview:
Lipid metabolism, metabolic diseases, and peroxisome
proliferator-activated receptors. Endocrinology. 144:2201–2207.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vidal-Puig AJ, Considine RV, Jimenez-Liñan
M, Werman A, Pories WJ, Caro JF and Flier JS: Peroxisome
proliferator-activated receptor gene expression in human tissues.
Effects of obesity, weight loss, and regulation by insulin and
glucocorticoids. J Clin Invest. 99:2416–2422. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lehrke M and Lazar MA: The many faces of
PPARgamma. Cell. 123:993–999. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Evans RM, Barish GD and Wang YX: PPARs and
the complex journey to obesity. Nat Med. 10:355–361. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fonseca V: Effect of thiazolidinediones on
body weight in patients with diabetes mellitus. Am J Med. 115(Suppl
8A): 42S–48S. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bünger M, Hooiveld GJ, Kersten S and
Müller M: Exploration of PPAR functions by microarray technology -
a paradigm for nutrigenomics. Biochim Biophys Acta. 1771:1046–1064.
2007. View Article : Google Scholar
|
|
15
|
Bajaj M, Suraamornkul S, Hardies LJ, Glass
L, Musi N and DeFronzo RA: Effects of peroxisome
proliferator-activated receptor (PPAR)-alpha and PPAR-gamma
agonists on glucose and lipid metabolism in patients with type 2
diabetes mellitus. Diabetologia. 50:1723–1731. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pickavance LC, Brand CL, Wassermann K and
Wilding JP: The dual PPARalpha/gamma agonist, ragaglitazar,
improves insulin sensitivity and metabolic profile equally with
pioglitazone in diabetic and dietary obese ZDF rats. Br J
Pharmacol. 144:308–316. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reifel-Miller A, Otto K, Hawkins E, Barr
R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA,
Rafaeloff-Phail R, et al: A peroxisome proliferator-activated
receptor alpha/gamma dual agonist with a unique in vitro profile
and potent glucose and lipid effects in rodent models of type 2
diabetes and dyslipidemia. Mol Endocrinol. 19:1593–1605. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harrity T, Farrelly D, Tieman A, Chu C,
Kunselman L, Gu L, Ponticiello R, Cap M, Qu F, Shao C, et al:
Muraglitazar, a novel dual (alpha/gamma) peroxisome
proliferator-activated receptor activator, improves diabetes and
other metabolic abnormalities and preserves beta-cell function in
db/db mice. Diabetes. 55:240–248. 2006. View Article : Google Scholar
|
|
19
|
Mittra S, Sangle G, Tandon R, Sharma S,
Roy S, Khanna V, Gupta A, Sattigeri J, Sharma L, Priyadarsiny P, et
al: Increase in weight induced by muraglitazar, a dual
PPARalpha/gamma agonist, in db/db mice: Adipogenesis/or oedema? Br
J Pharmacol. 150:480–487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Adeghate E, Adem A, Hasan MY, Tekes K and
Kalasz H: Medicinal chemistry and actions of dual and pan PPAR
modulators. Open Med Chem J. 5(Suppl 2): 93–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim T, Lee W, Jeong KH, Song JH, Park SH,
Choi P, Kim SN, Lee S and Ham J: Total synthesis and dual PPARα/γ
agonist effects of amorphastilbol and its synthetic derivatives.
Bioorg Med Chem Lett. 22:4122–4126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee W, Ham J, Kwon HC, Kim YK and Kim SN:
Anti-diabetic effect of amorphastilbol through PPARα/γ dual
activation in db/db mice. Biochem Biophys Res Commun. 432:73–79.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsuda J, Hosoda K, Itoh H, Son C, Doi K,
Hanaoka I, Inoue G, Nishimura H, Yoshimasa Y, Yamori Y, et al:
Increased adipose expression of the uncoupling protein-3 gene by
thiazolidinediones in Wistar fatty rats and in cultured adipocytes.
Diabetes. 47:1809–1814. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Emilsson V, O’Dowd J, Wang S, Liu YL,
Sennitt M, Heyman R and Cawthorne MA: The effects of rexinoids and
rosiglitazone on body weight and uncoupling protein isoform
expression in the Zucker fa/fa rat. Metabolism. 49:1610–1615. 2000.
View Article : Google Scholar
|
|
25
|
Campbell RK: Clarifying the role of
incretin-based therapies in the treatment of type 2 diabetes
mellitus. Clin Ther. 33:511–527. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahrén B: The future of incretin-based
therapy: Novel avenues - novel targets. Diabetes Obes Metab.
13(Suppl 1): 158–166. 2011. View Article : Google Scholar
|
|
27
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nissen SE and Wolski K: Effect of
rosiglitazone on the risk of myocardial infarction and death from
cardiovascular causes. N Engl J Med. 356:2457–2471. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kermani A and Garg A:
Thiazolidinedione-associated congestive heart failure and pulmonary
edema. Mayo Clin Proc. 78:1088–1091. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alonso A, Sasin J, Bottini N, Friedberg I,
Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J and Mustelin
T: Protein tyrosine phosphatases in the human genome. Cell.
117:699–711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moller DE: New drug targets for type 2
diabetes and the metabolic syndrome. Nature. 414:821–827. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tonks NK: Protein tyrosine phosphatases:
From genes, to function, to disease. Nat Rev Mol Cell Biol.
7:833–846. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Elchebly M, Payette P, Michaliszyn E,
Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J,
Chan CC, et al: Increased insulin sensitivity and obesity
resistance in mice lacking the protein tyrosine phosphatase-1B
gene. Science. 283:1544–1548. 1999. View Article : Google Scholar : PubMed/NCBI
|
